Utah Retirement Systems increased its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 14.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,600 shares of the medical research company’s stock after purchasing an additional 1,300 shares during the period. Utah Retirement Systems’ holdings in PRA Health Sciences were worth $1,168,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Price Capital Management Inc. bought a new stake in PRA Health Sciences in the third quarter worth $121,000. Twin Tree Management LP bought a new stake in PRA Health Sciences in the second quarter worth $120,000. Mount Yale Investment Advisors LLC increased its position in PRA Health Sciences by 103.6% in the second quarter. Mount Yale Investment Advisors LLC now owns 1,704 shares of the medical research company’s stock worth $159,000 after purchasing an additional 867 shares during the last quarter. Parallel Advisors LLC increased its position in PRA Health Sciences by 930.9% in the third quarter. Parallel Advisors LLC now owns 1,804 shares of the medical research company’s stock worth $199,000 after purchasing an additional 1,629 shares during the last quarter. Finally, Bremer Trust National Association bought a new stake in PRA Health Sciences in the third quarter worth $205,000. Institutional investors own 97.42% of the company’s stock.
PRAH stock opened at $103.07 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 1.22. PRA Health Sciences Inc has a twelve month low of $79.20 and a twelve month high of $121.98. The firm has a market cap of $6.91 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 1.54 and a beta of 0.77.
PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, October 31st. The medical research company reported $1.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.07 by $0.06. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The business had revenue of $717.60 million for the quarter, compared to analysts’ expectations of $729.63 million. During the same quarter in the previous year, the business posted $0.88 earnings per share. The business’s revenue was up 23.3% compared to the same quarter last year. As a group, analysts anticipate that PRA Health Sciences Inc will post 3.93 EPS for the current fiscal year.
Several brokerages recently weighed in on PRAH. Evercore ISI began coverage on shares of PRA Health Sciences in a research report on Thursday, October 4th. They issued an “inline” rating and a $120.00 price target on the stock. Robert W. Baird boosted their price target on shares of PRA Health Sciences from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 11th. BidaskClub cut shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday. UBS Group began coverage on shares of PRA Health Sciences in a research report on Tuesday, October 9th. They issued a “neutral” rating on the stock. Finally, SunTrust Banks boosted their price target on shares of PRA Health Sciences to $120.00 and gave the stock a “buy” rating in a research report on Monday, November 5th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. PRA Health Sciences currently has a consensus rating of “Buy” and an average price target of $111.50.
PRA Health Sciences Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: Call Option
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.